Luigi Lenaz

2.2k total citations
56 papers, 1.8k citations indexed

About

Luigi Lenaz is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luigi Lenaz has authored 56 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 20 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luigi Lenaz's work include Cancer therapeutics and mechanisms (15 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Research Studies (9 papers). Luigi Lenaz is often cited by papers focused on Cancer therapeutics and mechanisms (15 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Research Studies (9 papers). Luigi Lenaz collaborates with scholars based in Germany, United States and Netherlands. Luigi Lenaz's co-authors include J Page, W. Achterrath, P. Preusser, Jochen Meyer, U. Fink, H. Wilke, H J Meyer, A. Heinicke, H. Wilke and U. Gunzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Luigi Lenaz

55 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luigi Lenaz Germany 20 823 792 449 351 307 56 1.8k
Axel Grothey United States 23 2.0k 2.5× 1.0k 1.3× 515 1.1× 654 1.9× 184 0.6× 82 3.3k
Muhammad Wasif Saif United States 25 1.7k 2.1× 639 0.8× 475 1.1× 562 1.6× 261 0.9× 129 2.7k
Samir D. Undevia United States 21 1.3k 1.6× 809 1.0× 195 0.4× 1.1k 3.0× 297 1.0× 49 2.4k
G Winde Germany 26 869 1.1× 364 0.5× 815 1.8× 405 1.2× 84 0.3× 85 2.0k
André Planting Netherlands 31 1.6k 1.9× 720 0.9× 362 0.8× 923 2.6× 72 0.2× 71 2.6k
Chueh‐Chuan Yen Taiwan 23 1.2k 1.4× 708 0.9× 821 1.8× 541 1.5× 57 0.2× 57 2.3k
Albert J. ten Tije Netherlands 25 1.4k 1.7× 506 0.6× 391 0.9× 337 1.0× 56 0.2× 83 2.1k
Bach Ardalan United States 22 1.1k 1.4× 453 0.6× 311 0.7× 601 1.7× 107 0.3× 105 1.9k
W. Achterrath Germany 19 961 1.2× 916 1.2× 576 1.3× 443 1.3× 17 0.1× 53 1.7k
Giuseppina Catalano Italy 28 1.4k 1.7× 835 1.1× 377 0.8× 268 0.8× 25 0.1× 72 2.2k

Countries citing papers authored by Luigi Lenaz

Since Specialization
Citations

This map shows the geographic impact of Luigi Lenaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Lenaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Lenaz more than expected).

Fields of papers citing papers by Luigi Lenaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Lenaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Lenaz. The network helps show where Luigi Lenaz may publish in the future.

Co-authorship network of co-authors of Luigi Lenaz

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Lenaz. A scholar is included among the top collaborators of Luigi Lenaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Lenaz. Luigi Lenaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Beijnen, Jos H., et al.. (2008). Complexation Study of the Anticancer Agent EO-9 with 2-hydroxypropyl-β-Cyclodextrin. Drug Development and Industrial Pharmacy. 34(10). 1130–1139. 3 indexed citations
3.
Rajeshkumar, N.V., et al.. (2007). Effect of SPI-1620 on tumor perfusion and uptake of paclitaxel in a melanoma model. Molecular Cancer Therapeutics. 6. 1 indexed citations
4.
Nuijen, Bastiaan, et al.. (2007). Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS PharmSciTech. 8(3). E78–E87. 13 indexed citations
5.
Vainchtein, Liia D., Hilde Rosing, Dorla Mirejovsky, et al.. (2006). Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry. Journal of Mass Spectrometry. 41(10). 1268–1276. 9 indexed citations
6.
Vainchtein, Liia D., Hilde Rosing, Dorla Mirejovsky, et al.. (2006). Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer. Journal of Pharmaceutical and Biomedical Analysis. 43(1). 285–292. 10 indexed citations
7.
Phillips, Roger M., Paul M. Loadman, Victor Palit, et al.. (2005). Phase I/II clinical evaluation of intravesical EOquin (EO9) against superficial bladder cancer. Cancer Research. 65. 940–940. 2 indexed citations
8.
Miller, Kathy D., et al.. (2003). A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer. Investigational New Drugs. 22(1). 69–73. 15 indexed citations
9.
Klaassen, U., Hans‐Joachim Wilke, A. Harstrick, et al.. (1998). Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study. Annals of Oncology. 9(1). 45–50. 13 indexed citations
10.
Gatzemeier, U., et al.. (1992). Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer.. Journal of Clinical Oncology. 10(5). 818–823. 12 indexed citations
11.
Martín, Miguel, Eduardo Díaz‐Rubio, Antonio Casado, et al.. (1992). Carboplatin: an active drug in metastatic breast cancer.. Journal of Clinical Oncology. 10(3). 433–437. 61 indexed citations
12.
Achterrath, W., et al.. (1992). Simultaneous Radiotherapy and Chemotherapy with Carboplatin in Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase II Study. Cancer Investigation. 10(5). 349–355. 17 indexed citations
13.
Stahl, M., H. Wilke, P. Preusser, et al.. (1991). Etoposide, Leukovorin and 5-Fluorouracil (ELF) in Advanced Gastric Carcinoma – Final Results of a Phase-II Study in Elderly Patients or Patients with Cardiac Risk. Oncology Research and Treatment. 14(4). 314–318. 5 indexed citations
14.
Eiermann, W., et al.. (1991). Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Cancer Chemotherapy and Pharmacology. 27(5). 389–393. 6 indexed citations
15.
Niederle, N., et al.. (1991). Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. Cancer Chemotherapy and Pharmacology. 28(1). 59–62. 5 indexed citations
16.
Wilke, H., P. Preusser, U. Fink, et al.. (1990). High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk. Investigational New Drugs. 8(1). 65–70. 43 indexed citations
17.
Wilke, H., P. Preusser, U. Fink, et al.. (1989). Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.. Journal of Clinical Oncology. 7(9). 1318–1326. 228 indexed citations
18.
Wilke, H., W. Achterrath, Hans‐Joachim Schmoll, et al.. (1988). Etoposide and Split-Dose Cisplatin in Small-Cell Lung Cancer. American Journal of Clinical Oncology. 11(5). 572–578. 18 indexed citations
19.
Preusser, P., W. Achterrath, H. Wilke, et al.. (1988). Chemotherapy of gastric cancer. Cancer Treatment Reviews. 15(4). 257–277. 73 indexed citations
20.
Lenaz, Luigi & Frederick S. Philips. (1970). Effects of arabinosylcytosine nucleosides on DNA synthesis in rats.. PubMed. 30(7). 1961–2. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Axel Grothey Breakdown of academic impact, for papers by Muhammad Wasif Saif Breakdown of academic impact, for papers by Samir D. Undevia Breakdown of academic impact, for papers by G Winde Breakdown of academic impact, for papers by André Planting Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by Albert J. ten Tije Breakdown of academic impact, for papers by Bach Ardalan Breakdown of academic impact, for papers by W. Achterrath Breakdown of academic impact, for papers by Giuseppina Catalano
Rankless by CCL
2026